2020 MSU and #MyositisLIFE Sponsors
Learn more about our sponsors
Empowering Myositis Sponsors
Corbus Pharmaceuticals
Study researchers are actively recruiting participants for a global, 12-month Phase 3 study testing lenabasum for dermatomyositis. If you are interested in participating or learning more, visit: https://www.corbuspharma.com/clinical-trials/phase-3-study-in-dermatomyositis. The study is organized by Corbus Pharmaceuticals, a company focused on the development and commercialization of novel therapeutics for inflammatory and fibrotic diseases by harnessing its platform of endocannabinoid system-targeting drug candidates. The company’s lead product candidate, lenabasum, is an oral, selective cannabinoid receptor type 2 agonist designed to reverse chronic inflammation and halt fibrotic processes.
Kezar Life Sciences
Founded in 2015 and based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Kezar believes that the immunoproteasome is a validated target for the treatment of a wide variety of autoimmune diseases given the compelling published activity seen with non-selective proteasome inhibitors administered to patients with severe autoimmune diseases. Kezar is currently recruiting patients to participate in Phase 2 clinical trials. The diseases being studied in these trials are: lupus nephritis, dermatomyositis, polymyositis, autoimmune hemolytic anemia, and immune thrombocytopenia.
Understanding Myositis Sponsors
CSI Pharmacy
CSI Pharmacy is a nationwide specialty pharmacy, founded by pharmacists, dedicated to servicing patients with chronic and rare illnesses requiring complex care. We are invested in improving the health—and the lives—of the people we serve by offering expert clinicians, passionate advocates, committed healthcare partners and strategic reimbursement experts. Our goal is to optimize patient outcomes, while treating patients as if they were members of our family. Twenty percent of the patients we treat have a form of myositis. We are proud to be a sponsor of Myositis Awareness Month!
Orphazyme A/S
Orphazyme is a late-stage biopharmaceutical company focused on developing novel treatment options for patients with rare, orphan diseases. Our work is focused on the cell-protective properties of the heat-shock response, a natural defense mechanism in all our cells. Orphazyme’s lead compound, arimoclomol, is being developed as a potential treatment for several protein-misfolding diseases, including sporadic inclusion body myositis (sIBM). A phase 2/3 clinical trial investigating the use of arimoclomol for sIBM is ongoing with results expected in the first half of 2021.
Ra Pharmaceuticals
Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients with rare diseases.
Ra Pharma’s lead clinical candidate is zilucoplan, an investigational, synthetic, macrocyclic peptide discovered using the Company’s proprietary drug discovery technology. The peptide is designed to bind and inhibit complement component 5 (C5). Zilucoplan is being developed for the treatment of generalized myasthenia gravis (gMG), immune-mediated necrotizing myopathy (IMNM), amyotrophic lateral sclerosis (ALS), and other tissue-based complement-mediated disorders with high unmet medical need. Ra Pharma is currently enrolling a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical trial to assess zilucoplan for the treatment of IMNM.
Diplomat Specialty Infusion Group
Diplomat Speciality Infusion Group is a nationwide specialty pharmacy and infusion group.
Sponsorship opportunities are available
MSU is instrumental in improving the lives of people living with myositis (idiopathic inflammatory myopathies), a group of rare, complicated autoimmune muscle, skin, and often multi-organ diseases, through education, support, awareness, advocacy, access to research, and need-based financial assistance.
We are a fast-growing patient-led 501(c)(3) nonprofit organization with the experience needed to support and advocate for myositis patients and caregivers. Myositis affects the whole person and every aspect of their life. Understanding this disease isn’t limited to symptoms, we push for the inclusion of the patient voice in research and clinical care, and we work to empower the community to acknowledge patients and caregivers as equals – a part of a team – in their healthcare management.
We provide more than support. We continually work hard as an all-volunteer organization providing patient-centered programs and services and building unique and meaningful partnerships in the rare disease community. Technology is a driving force in our continued growth and success; educating, supporting, and connecting patients, caregivers, and family members with one another, and with doctors, researchers, clinical trials, partners, and patient-first focused providers.
Sponsorships include both our comprehensive myositis website, Understandingmyositis.org, and our #MyositisLIFE program and website; giving a voice to patients and caregivers.
#MyositisLIFE is our newest program with a dedicated interactive community-based website, and it provides a solution to a missing piece in awareness and research; the patient voice.
